In cervical cancer, HOXA11-AS silencing was shown to decrease the expression of matrix metalloproteinase-2 (MMP-2), MMP-9, and vascular endothelial growth factor and increase the number of CD133+CD44+ cells, indicating an increase in the cancer stem cell population14. Here, VEGFA is linked to cervical cancer.